Education
About Us
Working with TipRanks
Follow Us
SpyGlass Pharma (SGP)
NASDAQ:SGP
SGP Stock Chart & Stats
$27.55
-$0.28(-1.01%)
―
--
Day’s Range― - ―
52-Week Range$20.16 - $32.44
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,317,413
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SGP FAQ
What was SpyGlass Pharma’s price range in the past 12 months?
SpyGlass Pharma lowest stock price was $20.16 and its highest was $32.44 in the past 12 months.
What is SpyGlass Pharma’s market cap?
Currently, no data Available
When is SpyGlass Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SpyGlass Pharma’s earnings last quarter?
Currently, no data Available
Is SpyGlass Pharma overvalued?
According to Wall Street analysts SpyGlass Pharma’s price is currently Undervalued.
Does SpyGlass Pharma pay dividends?
SpyGlass Pharma does not currently pay dividends.
What is SpyGlass Pharma’s EPS estimate?
SpyGlass Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpyGlass Pharma have?
SpyGlass Pharma has 33,317,413 shares outstanding.
What happened to SpyGlass Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SpyGlass Pharma?
Currently, no hedge funds are holding shares in SGP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpyGlass Pharma
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.